nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.10.2012 | Research Paper

Biomarkers of cancer metastasis through the lymphovascular system: future perspectives

verfasst von: Stanley P. L. Leong, Marlys Witte

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Cancer progression from the primary site to the regional lymph nodes and beyond to the distant sites through the lymphovascular system is genetically determined. In general, sentinel lymph node in the regional lymph nodes is the gateway for metastasis. Biomarkers are becoming increasingly important to define different phases of metastasis. With further understanding of the molecular mechanisms of metastasis, more targets are available for selective therapeutic intervention so that effective therapy can be delivered against cancer in a more personalized approach.

Leong SP (2006) Proceedings of the 1st International Symposium on Cancer Metastasis and Lymphovascular System: basis for rational therapy, 28–30 April 2005, San Francisco, California, USA. Cancer Metastasis Rev 25(2):157–294

Leong SP (2007) Cancer metastasis and the lymphovascular system : basis for rational therapy. Cancer treatment and research. Springer, New YorkCrossRef

Leong SP (2009) From local invasion to metastatic cancer; involvement of distant sites through the lymphovascular system. Humana Press/Springer, New York

Leong SP (2011) The pivotal role of the lymphovascular system in cancer metastasis. J Surg Oncol 103:639–641PubMedCrossRef

Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399PubMedCrossRef

Reintgen D, Cruse CW, Wells K et al (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220:759–767PubMedCrossRef

Leong SP (2004) Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 11:192S–197SPubMed

Morton DL, Cochran AJ, Thompson JF (2005) Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242:302–311; discussion 311–313PubMed

Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol 12:2229–2234PubMed

10.

Leong SP, Gershenwald JE, Soong SJ et al (2011) Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol 103:538–549PubMedCrossRef

11.

Thompson JF, Soong SJ, Balch CM et al (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29:2199–2205PubMedCrossRef

12.

Gershenwald JE, Soong SJ, Balch CM (2010) TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol 17:1475–1477PubMedCrossRef

13.

Baehner FL, Li R, Jenkins T et al (2012) The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 19:1034–1042PubMedCrossRef

14.

Futreal PA, Coin L, Marshall M et al (2004) A census of human cancer genes. Nat Rev Cancer 4:177–183PubMedCrossRef

15.

Baehner FL, Lee M, Demeure MJ et al (2011) Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 103:563–573PubMedCrossRef

16.

Becker D, Mihm MC, Hewitt SM et al (2006) Markers and tissue resources for melanoma: meeting report. Cancer Res 66:10652–10657PubMedCrossRef

17.

Murphy MJ (2012) Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. Humana Press/Springer, New YorkCrossRef

18.

Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10:811–812PubMedCrossRef

19.

Beecher C (2002) Metabolomics: the newest “omics” sciences. Innov Pharm Technol 2:57–64

20.

Witte MH (2011) Translational/personalized medicine, pharmaco/surgico/radiogenomics, lymphatic spread of cancer, and medical ignoromes. J Surg Oncol 103:501–507PubMedCrossRef

21.

Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1–10PubMedCrossRef

22.

van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef

23.

Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 346:1937–1947PubMedCrossRef

24.

Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570–580PubMedCrossRef

25.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef

26.

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef

27.

Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRef

28.

Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819PubMedCrossRef

29.

Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363–366PubMedCrossRef

30.

Weinberg RA (2007) The biology of cancer. Garland Science, New York

31.

Paget G (1889) Remarks on a case of alternate partial anaesthesia. Br Med J 1:1–3PubMedCrossRef

32.

McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

33.

Nass SJ, Moses HL (eds) (2007) Cancer biomarkers: the promises and challenges of improving detection and treatment. National Academies Press, Washington

34.

Hellman S (1997) Darwin’s clinical relevance. Cancer 79:2275–2281PubMedCrossRef

35.

Tobler NE, Detmar M (2006) Tumor and lymph node lymphangiogenesis—impact on cancer metastasis. J Leukoc Biol 80:691–696PubMedCrossRef

36.

Rinderknecht M, Detmar M (2008) Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 216:347–354PubMedCrossRef

37.

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456PubMedCrossRef

38.

Morton DL, Hoon DS, Cochran AJ (2003) Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238:538–549; discussion 549–550PubMed

Titel: Biomarkers of cancer metastasis through the lymphovascular system: future perspectives
verfasst von: Stanley P. L. Leong
Marlys Witte
Publikationsdatum: 01.10.2012
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 7/2012
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9522-0

Springer Medizin

Biomarkers of cancer metastasis through the lymphovascular system: future perspectives

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Stromal biomarkers in breast cancer development and progression

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?

Rigorous quantitative sciences integration—the foundation of high-dimensional genomic research

Molecular profiling for personalized cancer care

The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie